These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 36337917)

  • 1. Plasminogen Activator Inhibitor-1: Another String in the Platelet-Derived Extracellular Vesicles Bow?
    Arangalage D; Franck G; Caligiuri G
    JACC Basic Transl Sci; 2022 Oct; 7(10):998-1000. PubMed ID: 36337917
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Circulating platelet-derived extracellular vesicles are decreased after remote ischemic preconditioning in patients with coronary disease: A randomized controlled trial.
    Reddel CJ; Pennings GJ; Lau JK; Chen VM; Kritharides L
    J Thromb Haemost; 2021 Oct; 19(10):2605-2611. PubMed ID: 34196106
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of platelet-derived growth factor isoforms on plasminogen activation by periodontal ligament and gingival fibroblasts.
    Agis H; Bauer M; Knebl G; Watzek G; Gruber R
    J Periodontal Res; 2008 Jun; 43(3):334-42. PubMed ID: 18447857
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasma and platelet plasminogen activator inhibitor-1 in patients with acute myocardial infarction.
    Soeki T; Tamura Y; Fukuda N; Ito S
    Jpn Circ J; 2000 Aug; 64(8):547-53. PubMed ID: 10952148
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Performance of plasminogen activator inhibitor-1 as a biomarker in patients undergoing coronary angiography: Analytical and biological considerations.
    Jung RG; Simard T; Di Santo P; Labinaz A; Moreland R; Duchez AC; Majeed K; Motazedian P; Rochman R; Jung Y; Hibbert B
    Diab Vasc Dis Res; 2019 Sep; 16(5):478-482. PubMed ID: 31064214
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oxygen radical scavenging agents as adjuvant therapy with tissue plasminogen activator in a canine model of coronary thrombolysis.
    Przyklenk K; Kloner RA
    Cardiovasc Res; 1993 Jun; 27(6):925-34. PubMed ID: 8221780
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effects of residual platelets in plasma on plasminogen activator inhibitor-1 and plasminogen activator inhibitor-1-related assays.
    Pieters M; Barnard SA; Loots DT; Rijken DC
    PLoS One; 2017; 12(2):e0171271. PubMed ID: 28158230
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasminogen activator inhibitor activity and other fibrinolytic variables in patients with coronary artery disease.
    Aznar J; Estellés A; Tormo G; Sapena P; Tormo V; Blanch S; España F
    Br Heart J; 1988 May; 59(5):535-41. PubMed ID: 3132963
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antithrombotic treatment (argatroban vs. heparin) in coronary angioplasty in angina pectoris: effects on inflammatory, hemostatic, and endothelium-derived parameters.
    Suzuki S; Matsuo T; Kobayashi H; Matsuo M; Shimamo C; Koide M; Sakamoto S
    Thromb Res; 2000 May; 98(4):269-79. PubMed ID: 10822073
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tissue-type plasminogen activator is not necessary for platelet-derived growth factor-c activation.
    Riehle KJ; Johnson MM; Johansson F; Bauer RL; Hayes BJ; Gilbertson DG; Haran AC; Fausto N; Campbell JS
    Biochim Biophys Acta; 2014 Feb; 1842(2):318-25. PubMed ID: 24269585
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Developmental differences in the expression and modulation of extracellular matrix proteases and inhibitors in mouse skin fibroblasts.
    Island E; Wu H; Warburton D; Anderson K; Tuan TL
    Wound Repair Regen; 1999; 7(6):467-76. PubMed ID: 10633006
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Temporal expression of urokinase plasminogen activator, plasminogen activator inhibitor and gelatinase-B in chronic wound fluid switches from a chronic to acute wound profile with progression to healing.
    Wysocki AB; Kusakabe AO; Chang S; Tuan TL
    Wound Repair Regen; 1999; 7(3):154-65. PubMed ID: 10417751
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Changes in plasminogen activator inhibitor 1 and tissue-type plasminogen activator during exercise in patients with coronary artery disease.
    Rydzewski A; Sakata K; Kobayashi A; Yamazaki N; Urano T; Takada Y; Takada A
    Haemostasis; 1990; 20(5):305-12. PubMed ID: 2127039
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Endogenous tissue plasminogen activator and platelet reactivity as risk factors for reocclusion after recanalization of chronic total coronary occlusions.
    Terres W; Lund GK; Hübner A; Ehlert A; Reuter H; Hamm CW
    Am Heart J; 1995 Oct; 130(4):711-6. PubMed ID: 7572577
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Contribution of platelets to increased plasminogen activator inhibitor type 1 in severe preeclampsia.
    Gilabert J; Estellés A; Aznar J; España F; Andrés C; Santos T; Vallés J
    Thromb Haemost; 1990 Jun; 63(3):361-6. PubMed ID: 2144918
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plasma levels of tissue plasminogen activator and plasminogen activator inhibitor-1 are correlated with the presence of transplant coronary artery disease in cardiac transplant recipients.
    Warshofsky MK; Wasserman HS; Wang W; Teng P; Sciacca R; Apfelbaum M; Schwartz A; Michler RE; Mancini DM; Cannon PJ; Rabbani LE
    Am J Cardiol; 1997 Jul; 80(2):145-9. PubMed ID: 9230149
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of plasminogen activator inhibitor-1, tissue type plasminogen activator antigen, fibrinogen, and D-dimer levels in various age decades in patients with type 2 diabetes mellitus and stable coronary artery disease (from the BARI 2D trial).
    McBane RD; Hardison RM; Sobel BE;
    Am J Cardiol; 2010 Jan; 105(1):17-24. PubMed ID: 20102884
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lysis of plasminogen activator-resistant platelet-rich coronary artery thrombus with combined bolus injection of recombinant tissue-type plasminogen activator and antiplatelet GPIIb/IIIa antibody.
    Yasuda T; Gold HK; Leinbach RC; Saito T; Guerrero JL; Jang IK; Holt R; Fallon JT; Collen D
    J Am Coll Cardiol; 1990 Dec; 16(7):1728-35. PubMed ID: 2123910
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Thrombolytic therapy: enhancement by platelet and platelet-derived mediator antagonists.
    Willerson JT; Golino P; McNatt J; Eidt J; Yao SK; Buja LM
    Mol Biol Med; 1991 Apr; 8(2):235-43. PubMed ID: 1806765
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Blood platelet plasminogen activator inhibitor: two different pools of endothelial cell type plasminogen activator inhibitor in human blood.
    Sprengers ED; Akkerman JW; Jansen BG
    Thromb Haemost; 1986 Jun; 55(3):325-9. PubMed ID: 3092389
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.